Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) Receives $14.30 Average Target Price from Analysts

Shares of Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) have been given a consensus rating of “Moderate Buy” by the eight brokerages that are currently covering the firm, MarketBeat reports. One research analyst has rated the stock with a sell rating, two have issued a hold rating and five have given a buy rating to the company. The average 1 year price target among analysts that have updated their coverage on the stock in the last year is $14.30.

A number of brokerages have recently commented on VNDA. Wall Street Zen cut shares of Vanda Pharmaceuticals from a “sell” rating to a “strong sell” rating in a report on Saturday, May 9th. HC Wainwright reaffirmed a “buy” rating on shares of Vanda Pharmaceuticals in a report on Thursday, June 4th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Vanda Pharmaceuticals in a report on Monday, April 20th. Finally, Truist Financial assumed coverage on Vanda Pharmaceuticals in a research report on Thursday, March 5th. They issued a “buy” rating and a $18.00 price target on the stock.

Vanda Pharmaceuticals Stock Down 0.3%

Shares of NASDAQ:VNDA opened at $6.12 on Wednesday. The company has a market capitalization of $368.00 million, a PE ratio of -1.51 and a beta of 0.62. The company has a current ratio of 2.16, a quick ratio of 2.15 and a debt-to-equity ratio of 0.01. Vanda Pharmaceuticals has a twelve month low of $4.14 and a twelve month high of $9.94. The firm has a 50 day simple moving average of $6.32 and a 200-day simple moving average of $7.09.

Vanda Pharmaceuticals (NASDAQ:VNDA) last issued its quarterly earnings data on Wednesday, May 6th. The biopharmaceutical company reported ($0.82) earnings per share for the quarter, missing the consensus estimate of ($0.69) by ($0.13). The company had revenue of $51.72 million for the quarter, compared to analysts’ expectations of $54.98 million. Vanda Pharmaceuticals had a negative return on equity of 32.26% and a negative net margin of 109.99%. On average, equities analysts predict that Vanda Pharmaceuticals will post -2.2 EPS for the current fiscal year.

Institutional Trading of Vanda Pharmaceuticals

Several institutional investors and hedge funds have recently added to or reduced their stakes in VNDA. Torren Management LLC purchased a new stake in Vanda Pharmaceuticals during the 4th quarter valued at approximately $25,000. Russell Investments Group Ltd. increased its stake in Vanda Pharmaceuticals by 456.6% in the 3rd quarter. Russell Investments Group Ltd. now owns 6,495 shares of the biopharmaceutical company’s stock valued at $32,000 after buying an additional 5,328 shares during the period. Quarry LP acquired a new position in Vanda Pharmaceuticals in the 3rd quarter valued at $53,000. Cerity Partners LLC acquired a new position in Vanda Pharmaceuticals in the 2nd quarter valued at $69,000. Finally, Boothbay Fund Management LLC acquired a new position in Vanda Pharmaceuticals in the 3rd quarter valued at $72,000. 88.14% of the stock is owned by hedge funds and other institutional investors.

Vanda Pharmaceuticals Company Profile

Vanda Pharmaceuticals Inc is a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies for central nervous system (CNS) disorders and rare diseases. The company’s research and development efforts center on sleep-wake regulation, mood disorders, and movement disorders. Vanda’s mission is to address unmet medical needs by advancing novel molecules through clinical trials and regulatory review.

Vanda’s flagship commercial product is Hetlioz (tasimelteon), a melatonin receptor agonist approved by the U.S.